The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

Burnett, Alan Kenneth, Kell, William J., Goldstone, Anthony H., Milligan, Donald, Hunter, Ann, Prentice, Archie G., Russell, Nigel H., Gibson, Brenda, Wheatley, Keith and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 2006. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood -New York- 108 (11) , 8A-8A.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	48th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 09-12, 2006
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	24 Oct 2022 11:55
URI:	https://orca.cardiff.ac.uk/id/eprint/49735

Actions (repository staff only)

Edit Item